第一三共是一家為社會可持續發展做貢獻的創新型全球醫療保健公司，致力于發現、開發和提供新的標準療法，以提高世界各地患者的生活質量。第一三共專注制藥行業120余年，憑借其世界一流的科學和技術，為癌癥、心血管疾病和其他醫療需求遠未得到滿足的疾病患者研發新的治療方法和創新藥物。如欲了解更多信息，請訪問www.daiichisankyo.com<\/a>。<\/p> \n

\n \n \n \n \n \n \n \n \n \n
<optgroup id="kgssg"></optgroup>
<center id="kgssg"></center>
久久久亚洲欧洲日产国码二区
[1] Bardia A, et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+\/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial. ESMO Congress 2023. LBA11.<\/span><\/p> <\/td> \n <\/tr> \n
[2] National Cancer Institute. SEER cancer stat facts: female breast cancer subtypes. Accessed September 2023.<\/span><\/p> <\/td> \n <\/tr> \n
[3] Iqbal N, et al. Mol Biol Int<\/i>. 2014;852748.<\/span><\/p> <\/td> \n <\/tr> \n
[4] Lin M, et al. J Cancer<\/i>. 2020; 10.7150\/jca.48944.<\/span><\/p> <\/td> \n <\/tr> \n
[5] Lloyd M R, et al. Clin Cancer Res.<\/i> 2022; 28(5):821-30.<\/span><\/p> <\/td> \n <\/tr> \n
[6] Goldenberg D, et al. Oncotarget<\/i>. <\/i>2018;9(48): 28989-29006.<\/span><\/p> <\/td> \n <\/tr> \n
[7] Vidula N, et al. Breast Cancer Res Treat<\/i>. 2022 Aug;194(3):569-575.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
<\/p> \n
\n<\/div>"]; $("#dvExtra").html(content_array[0]);})();
<center id="kgssg"></center>